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ABSTRACT
Objective: We aimed to assess MET intratumoral heterogeneity and its potential 
impact on biomarker-based patient selection as well as potential surrogate biomarkers 
of MET activation.
Methods: Our study included 120 patients with non-squamous Non-small-cell 
Lung Cancer (nsNSCLC), of which 47 were incorporated in tissue microarrays (TMA). 
Four morphologically distinct tumor areas were selected to assess MET heterogeneity. 
MET positivity by immunohistochemistry (IHC) was defined as an above-median 
H-score and by +2/+3 staining intensity in >50% of tumor cells (Metmab criteria). 
MET FISH positivity was defined by MET/CEP7 ratio ≥ 2.0 and/or MET ≥ 5.0. MET 
staining pattern (cytoplasmic vs. membranous) and mesenchymal markers were 
investigated as surrogates of MET activation.
Results: Median MET H-score was 140 (range 0–400) and 47.8% of patients were 
MET positive by Metmab criteria. Eight cases (6.8%) were MET FISH positive and 
showed higher H-scores (p = 0.021). MET positivity by IHC changed in up to 40% of 
cases among different tumor areas, and MET amplification in 25–50%. Cytoplasmic 
MET staining and positivity for vimentin predicted poor survival (p = 0.042 and 0.047, 
respectively).
Conclusions: MET status is highly heterogeneous among different nsNSCLC 
tumor areas, hindering adequate patient selection for MET-targeted therapies. 
MET cytoplasmic staining and vimentin might represent surrogate markers for MET 
activation.
INTRODUCTION
Despite significant advances in diagnosis and 
treatment, lung cancer remains the leading cause of 
cancer death worldwide [1]. Non-small cell lung cancer 
(NSCLC) accounts for up to 85% of lung cancers, of which 
40% are adenocarcinomas [2]. During the last decade, 
considerable progress has been made in the knowledge 
of NSCLC biology. Several molecular alterations, such as 
mutations in the epidermal growth factor receptor (EGFR) 
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[3] or anaplastic lymphoma kinase (ALK) and ROS proto-
oncogene 1 (ROS1) rearrangements [4]predict response 
to specific targeted therapies. These developments have 
greatly impacted on patients’ outcome and quality of life 
[5–7].
MET was first identified in the late ‘80s, it is 
located on chromosome band 7q31 and encodes a 
heterodimeric transmembrane receptor with tyrosine 
kinase activity (RTK) [8, 9]. Activation of MET initiates 
a cascade of cellular signaling processes that ultimately 
lead to proliferation, reduced apoptosis, epithelial 
to mesenchymal transition (EMT) and an increased 
invasiveness and metastatic potential [10, 11]. MET 
pathway activation has been explained by different 
mechanisms such as genetic point mutations, gene 
amplification, post-translational activation, as well as in a 
ligand-dependent manner [12, 13].
The presence of MET protein overexpression and 
MET gene amplification in NSCLC are globally considered 
as adverse prognostic factors [14–17]. Consequently, 
many efforts have been made to develop MET-targeted 
agents [18, 19]. Clinical benefit was initially reported in 
patients with high serum levels of circulating HGF [20]or 
whose tumors harbored MET gene amplification [21]. In 
the MARQUEE [22] and the MetLung trials [23], patients 
were selected based on non-squamous histology and on 
MET immunohistochemical expression, respectively. Both 
trials failed to meet their primary endpoints, highlighting 
the need for predictive biomarkers for Met-directed 
treatment.
During the past few years, next-generation 
sequencing studies have revealed remarkable genetic and 
phenotypic differences among individual solid tumors 
[24] and also among different tumor areas and their 
metastases [25, 26]. This heterogeneity can interfere 
with biomarker-based treatment decisions, particularly 
when these are made based on material from small tumor 
biopsies.
Finally, a recent report in patients with gastric 
adenocarcinoma has suggested that MET staining 
pattern can predict MET gene amplification [27]. 
Moreover, in previous experiences with SCLC patients, 
we have observed that total MET protein expression 
does not always translate pathway activation and that 
signaling through MET can trigger EMT [28]. Thus, 
we hypothesized that the presence of a mesenchymal 
phenotype could translate MET pathway activation.
The primary aim of this study was to evaluate the 
potential impact of intra-tumor heterogeneity on MET 
evaluation and classification using different techniques and 
criteria. Furthermore, we sought to assess the correlation 
of MET status with other pathological and molecular 
characteristics. Finally and with exploratory purposes, 
we investigated potential surrogate markers of MET 
activity, such as MET staining pattern and the presence of 
mesenchymal markers by immunohistochemistry.
MATERIALS AND METHODS
Study population
Criteria for patient selection were non-squamous 
non-small cell lung carcinoma (nsNSCLC) histology and 
availability of tissue for the studies. A total of 124 tumor 
specimens from 120 patients diagnosed of nsNSCLC at 
our institution between 2009 and 2013 were included. 
Four of the 120 patients presented two different tumors, 
thus providing one extra specimen each. Material was 
available either from surgical resections, core-needle 
biopsies or cytological cell-blocks. Clinical data were 
extracted from medical records and included age, sex, 
smoking history, tumor disease stage and clinical follow-
up information.
Tissue microarray construction
Based on tissue availability, 47 of the patients 
were selected to construct tissue microarrays (TMAs) 
as outlined by Kononen et al. [29]. First, original 
Hematoxylin–Eosin (H&E) stained-sections were 
reviewed from each patient to identify different malignant 
areas and benign lung tissue. A total of six tissue cores 
with a 2 mm of diameter were obtained from each patient, 
four of them containing different histological areas of 
the carcinoma (named A, B, C and D) and two of them 
containing benign lung parenchyma. Two of the 47 
patients presented two different tumors, thus providing 
eight tumor cores each. This lead to a final number of 196 
tumor cores divided into six TMAs.
Fluorescence in situ hybridization
MET fluorescence in situ hybridization (FISH) 
evaluation was performed on unstained formalin-fixed 
and paraffin-embedded(FFPE) tissue sections from 
the whole tumor and the TMA samples, as previously 
described [30], using a MET/CEP7 probe cocktail 
(#06N05-020, Abbott Molecular Inc, Des Plaines, IL) 
according to manufacturer’s instructions. A minimum 
of fifty non-overlapping cells with hybridization signals 
were examined for each case with a BX51 fluorescence 
microscope (Olympus, Tokyo, Japan) and using the 
Cytovysion software (Applied Imaging, Grand Rapids 
MI). Tumors with MET/CEP7 ratio ≥ 2.0 (named “truly 
amplified”) and/or MET ≥ 5.0 copies (named “high 
polysomy”) were considered MET FISH positive [15, 31]. 
MET gains -defined as a mean copy number ≥ 2.5 copies 
in at least 10% of analysed nuclei- were also recorded.
Immunohistochemical assays
MET immunohistochemistry (IHC) evaluation 
was performed using anti-total c-MET (SP44) Rabbit 
Monoclonal as a primary antibody (#7904430, Ventana 
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Medical Systems, Tucson, AZ) and revealed using 
an Anti-RbOmniMap DAB Detection Kit (#760149, 
Ventana Medical Systems). The staining was carried out 
according to the manufacturer’s protocol on a Discovery 
XT platform (Ventana Medical Systems). The primary 
antibody was incubated for 60 minutes. IHC staining was 
evaluated by one pathologist using two different methods. 
The first one was an H-score, as initially described to 
evaluate EGFR expression [32]. Briefly, this score ranges 
from 0 to 400 and results from the combination of the 
staining intensity (0–4) and the percentage of positive 
tumoral cells (0–100%) in each sample. Tumor samples 
were considered positive if their H-score was above 
median. The second one was the method described by 
Spigel and collaborators [33], which divides tumors into 
two different categories: MET high for cases presenting 
strong MET staining (+2 or +3) in more than 50% of 
tumoral cells and MET low for cases not fulfilling the 
former criteria. Met staining pattern, i.e. predominantly 
membranous vs. cytoplasmic, was assessed as described 
elsewhere [27].
E-cadherin and vimentin as EMT immuno-
histochemical markers were evaluated semiquantitatively 
[34]. Anti-human E-cadherin (NCH-38) mouse monoclonal 
primary antibody (#IR059, Dako, Carpinteria, CA) and 
anti-Vimentin (V9) mouse monoclonal primary antibody 
(#IR630, Dako) were evaluated. Both were revealed using 
the EnVision Flex visualization system (#K8010, Dako) 
and carried out according to the manufacturer’s protocol 
using DakoAutostainer Plus. E-cadherin expression was 
evaluated as positive or “normal” when more than 50% of 
tumoral cells showed either membranous or cytoplasmatic 
staining. Vimentin expression was evaluated as positive or 
“acquired” when more than 5% of tumoral cells presented 
strong staining. For analysis purposes, samples showing 
positive E-cadherin expression were considered as having 
an epithelial phenotype, whereas samples showing 
acquired Vimentin staining were considered mesenchymal.
Statistical analysis
All 196 TMA cores were considered and analysed 
as individual cases to study the association between MET 
IHC and MET FISH with histopathological variables. 
These associations were analysed using Chi-square or 
two-sample T-tests as necessary. Heterogeneity between 
different cores (A, B, C and D) was assessed using 
Kappa agreement index for categorical variables (i.e. 
FISH categories) and intraclass correlation coefficient for 
continuous variables (i.e. MET H-score).
Survival analyses were only performed in those 
patients included in the TMAs as this was a more 
homogeneous population, being all surgically treated 
patients with early stage disease. Survival curves were 
obtained with the Kaplan-Meier method and significance 
of the differences in outcome was evaluated with the Cox 
regression test. Statistical analysis was carried out with 
SPSS version 13.0 (SPSS Inc., Chicago, IL). Data and 
statistical analysis reported are fully compliant with the 
REMARK guidelines [35].
RESULTS
Clinical and pathological characteristics of the 
study population
Patients’ median age was 66 years, 69% were 
males and 52% were current smokers. Forty percent 
of the study population had stage I disease and 85% 
were adenocarcinomas (Table 1). Most of the samples 
showed moderate or poor histological differentiation 
(Grades 2–3). The predominant histological patterns 
in adenocarcinomas were acinar or solid with mucin 
production, whereas lepidic and micropapillary patterns 
were less common.
Mutational data was available for more than 90% 
of the cases. KRAS and EGFR mutations were found in 
21% and 12% of the samples, respectively, whereas 2% of 
the cases presented ALK rearrangements. Patients included 
in the TMA study had similar characteristics, but with a 
higher proportion of patients with stage I disease (60%) 
and EGFR mutated cases (21%).
MET FISH analysis
MET status by FISH was evaluable in 117 out of 
124 tumors (94.4%). We found eight MET positive cases 
(6.8%; 8/117). Four of these cases exhibited a MET/CEP7 
ratio ≥ 2 (truly amplified) and the remaining four had 
five or more copies of the MET gene (high polysomy). 
MET gain was identified in 73 cases (62.4%), being most 
of them polysomic for chromosome 7 (n = 60) (Table 2). 
MET gains were more prevalent in adenocarcinomas with 
a predominantly solid histological pattern (p = 0.011) 
(data not shown). Different FISH patterns are illustrated 
in Supplementary Figure 1.
MET IHC
MET IHC was assessable in 115 out of 124 
tumors (92.7%). According to MetMab criteria, 55 cases 
(47.8%; 55/115) were classified as MET high, and 60 
cases (52.2%; 60/115) as MET low (Table 2). Median 
H-score was 140 (range 0–400). According to H-score, 
56 tumors were classified as positive (H-score > 140) and 
59 as negative (H-score ≤ 140). Comparing both scoring 
methods, three cases were classified differently, one case 
with an H-score of 140 was classified as MET high and 
two cases with H-scores of 160 and 180, respectively, 
were classified as MET low. MET membranous stain-
ing was generally coarser than cytoplasmic staining 
(Supplementary Figure 2).
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Heterogeneity assessment
Heterogeneity studies were focused on the TMA 
population, in which 171 out of 196 cores (87.2%) were 
assessable for histology, 176 (89.8%) for grade, 184 
(93.9%) for MET IHC and 180 (91.8%) for MET FISH. 
As expected, histological pattern and grade showed a 
highly heterogeneous distribution among different cores 
Table 1: Global study population and TMA patients’ characteristics
Global population1 (n = 120) TMA population2 (n = 47)
Age (yr)
 Median 66 66
 Range 41–92 41–80
Sex, n (%)
 Male 83 (69) 29 (62)
 Female 37 (31) 18 (38)
Smoking status, n (%)
 Never smoker 20 (17) 12 (25)
 Former smoker 37 (31) 14 (30)
 Current smoker 63 (52) 21 (45)
Stage, n (%)
 I3 50 (40) 29 (60)
 II 19 (15) 8 (16)
 III 20 (17) 10 (20)
 IV 35 (28) 2 (4)
Histology, n (%)
 Adenocarcinoma 106 (85) 44 (90)
 NOS 18 (15) 5 (10)
Histological Grade4, n (%)
 1 16 (20) 12 (30)
 2 33 (42) 17 (42)
 3 30 (38) 11 (28)
 Not assessable 27 4
KRAS, n (%)
 Wild-type 90 (79) 38 (83)
 Mutated 24 (21) 8 (17)
 Not Assessable 10 3
EGFR, n (%)
 Wild-type 101 (88) 38 (79)
 Mutated 14 (12) 10 (21)
 Not assessable 9 1
ALK, n (%)
 Not rearranged 106 (98) 39 (95)
 Rearranged 2 (2) 2 (5)
 Not assessable 16 8
1Includes 4 patients who had two different tumors (n = 124 tumors).
2Includes 2 patients who had two different tumors (n = 49 tumors).
3Includes 4 stage 0 patients.
4Only n = 106 adenocarcinomas. TMA, Tissue microarray; NOS, Not otherwise specified.
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(Kappa agreement index of 0.10 and 0.18, respectively, 
comparing A-B cores). When MET IHC status was 
analyzed considering the H-score as a continuous 
variable, intraclass correlation coefficient (ICC) was 0.47 
between cores A and B. When all four cores (A to D) 
were included in the analysis, ICC was 0.57. When cases 
were classified using MetMab criteria and divided into 
MET high and Met low, comparison of core A with the 
remaining three cores (B to D) revealed differences in 
classification in approximately 20–40% of the cases 
(Figure 1).
Regarding MET FISH analysis, when evaluated 
as a categorical variable (MET disomic, MET gain, 
MET positive), Kappa agreement index between cores 
A and B was 0.35. Regarding MET gain as a continuous 
variable, ICC between the four cores was 0.58. Among 
the three MET FISH positive cases found in the TMA 
population, four out of the 12 cores represented were 
FISH negative. Moreover, none of the cases was 
considered positive in all four cores (Figure 2). Intra-
tumor heterogeneity of MET by both IHC and FISH is 
illustrated in Figure 3.
Association between IHC and FISH
MET FISH positive cases had higher H-score 
values (p = 0.021) (Supplementary Figure 3). Among 
these, the four truly amplified cases had higher H-score 
values than those categorized as high polysomy 7, 
although these difference was not statistically significant 
(data not shown). However, no significant association 
was found between MET mean copy number and 
MET H-score considered as continuous variables 
(Supplementary Table 1). Applying the criteria recently 
proposed by Camidge et al. [36], only the four cases 
categorized as truly amplified would be considered 
MET positive tumors. Of these, one case had high-
level MET amplification (MET/CEP7 ratio ≥ 5) with 
an H-score of 400 and MET high by MetMab criteria, 
whereas the remaining three cases had an intermediate-
level of MET amplification (MET/CEP7 ratio ≥ 2.2- < 5), 
of which one was classified as MET high and the 
remaining two as MET low by IHC. Discordance between 
IHC and FISH is illustrated in Figure 4.
MET staining pattern and 
mesenchymal markers
MET staining pattern was assessable in 132 cores. 
Out of these, only 14 (10.6%; 14/132) corresponding to 
11 patients showed a predominantly cytoplasmic staining. 
Heterogeneity of MET staining pattern among different 
tumor cores was also observed (Figure 5). Three patients 
had predominantly cytoplasmic MET in two cores. The 
remaining 8 patients showed cytoplasmic staining in only 
one of the four cores. No patient had cytoplasmic MET 
in all four cores and none of the cores with cytoplasmic 
MET was FISH positive (Supplementary Figure 4). 
Interestingly, predominant cytoplasmic MET staining 
correlated with lower MET H-scores (p = 0.003), whereas 
non-smoking was associated with a membranous staining 
pattern (p = 0.042) (Table 3).
Table 2: MET IHC and MET FISH status among biopsy (left) and TMA (right) specimens
Global population1 (n = 115) TMA population (n = 49)
MET H-score
 Median 140 90
 Range 0–400 0–400
Metmab score, n (%)
 MET high 55 (48) 17 (35)
 MET low 60 (52) 32 (65)
Global population1 (n = 117) TMA population (n = 49)
MET FISH negative
 MET disomic 36 (30.8) 11 (23)
 MET gain 73 (62.4) 35 (71)
MET FISH positive2
 High polysomy 4 (3.4) 2 (4)
 Truly Amplified 4 (3.4) 1 (2)
1For FISH analysis, the core with the highest gene copy number value was selected. For IHC, H-score and Metmab score 
was calculated using all 4 cores (see Materials and Methods).
2FISH positivity was defined as the average number of MET copies ≥5 or a MET/CEP7 ratio ≥2. 
IHC, immunohistochemistry; TMA, Tissue microarray; FISH, fluorescence in situ hybridization.
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Figure 1: Metmab status discordance among different tumor cores. Differences in MET IHC classification among different 
areas represented in each core. The highest variability was observed between cores A and D and the lowest between A and C.
Figure 2: MET FISH discordance among different cores in FISH positive cases. Eight out of twelve cores are FISH positive. 
None of the cases shows FISH positivity in all four cores.
Figure 3: Tumor heterogeneity regarding MET status. CASE A. Two TMA cores of the same tumor sample with opposite FISH MET 
results: in the left a positive core showing a MET/CEP7 ratio ≥2, and in the right a MET negative disomic case. CASE B. Two TMA cores of the 
same tumor sample with opposite MET IHC results: at the left a positive +4 area, and at the right a completely negative area of the same tumor.
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Vimentin staining was assessable in 184 cores and 
E-cadherin in 181. A total of 19 cores corresponding to eight 
different patients (10.3%; 19/184) showed a mesenchymal 
phenotype (strong vimentin staining). All of these patients 
had a smoking history (five of them were current smokers 
and the remaining three were former smokers). Interestingly, 
the presence of a mesenchymal phenotype was associated 
with a predominantly cytoplasmic MET staining (p = 
0.042). Also, tumors showing mesenchymal features had 
significantly lower H-scores (p = 0.027), whereas the 
opposite occurred for E-cadherin positive tumors, which had 
significantly higher H-scores (p = 0.003) (Table 3).
Survival analysis (TMA cohort)
Median follow-up time was 73.2 months and 
median survival time was not reached. One-, two- 
and three-year survival rates were 93.7%, 80.6% 
and 73.1%, respectively. Patients whose tumor Met 
H-score values were below the median had shorter 
Figure 4: Discordance between FISH and IHC in individual tumors. CASE A. MET FISH positive case showing a MET/CEP7 
ratio ≥2 (left) and, the same case assessed by IHC showing negative staining (right). CASE B. MET FISH negative sample (left) with a high 
positive score by IHC (strong +4 membranous predominant staining) in the same sample (right).
Figure 5: Met IHC staining pattern discordance. A. and B. show different tumor cores from the same patient. A: predominantly 
cytoplasmic staining and B: predominantly membranous staining.
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survival times when compared with patients with 
above-median values, but thiswas not statistically 
significant (p = 0.175). Interestingly, patients with 
tumors showing either a predominantly cytoplasmic 
Met staining or expression of mesenchymal features 
(i.e. vimentin positivity) had shorter survival times, 
and these differences were statistically significant (p = 
0.042 and p = 0.047, respectively). Survival curves are 
illustrated in Figure 6.
DISCUSSION
Lung adenocarcinoma is a morphologically 
heterogeneous disease. Multiple histological patterns can 
be identified when surgical samples are evaluated [37]. 
This may be due to underlying genetic heterogeneity 
as described for other neoplasms [38, 39] as well as for 
NSCLC [40, 41]. In routine clinical practice, we use biopsy 
or cytology samples, which contain only a small fraction 
of tumor, to make treatment decisions and select patients 
for clinical trials. In our study, patient classification by IHC 
could vary in up to 40% among different tumor areas.
We also corroborated that de novo MET 
amplification is a rare event, in the range of other genetic 
alterations such as ROS or ALK rearrangements [42]. 
Furthermore, although FISH positive cases showed 
significantly higher MET H-score values, correlation 
between MET gains and total MET protein expression was 
poor. We also identified cases with evident discordance 
between MET IHC and FISH, for which the underlying 
mechanism is not clear. However, it is consistent with 
findings from other studies [43].
The difficulty of finding the correct predictive 
biomarker for MET-targeted therapies may explain, at least 
in part, the lack of success of the two largest trials testing 
MET inhibitors combined with Erlotinib in NSCLC patients. 
The MARQUEE trial [22] selected patients with nsNSCLC 
histology based on data of a phase II with Tivantinib [44]. 
The MetLung trial [23, 33], also based on phase II data 
with Onartuzumab [33], performed a more restrictive 
selection, including only patients with +2/+3 staining in at 
least 50% of tumor cells. Interestingly, a molecular-based 
post-hoc analysis was conducted on approximately 40% 
of the patients (based on tissue availability) participating 
in the MARQUEE trial. This analysis revealed a survival 
benefit in those patients with high MET protein expression 
determined by by MetMab criteria (HR 0.7; p = 0.03) [45].
Another strategy for the development of MET 
inhibitors in NSCLC relies on patient selection based 
on MET gains or gene amplification. In the MARQUEE 
study, no statistically significant differences were observed 
in overall survival between MET amplified and non-
amplified cases (HR 0.83; p = 0.34) [45]. Conversely, a 
subgroup analysis of the phase II study with Onartuzumab 
revealed a survival benefit for EGFR wild-type and MET 
FISH positive [15] patients receiving the combined 
Table 3: Association of MET IHC with other histopathological features in TMA samples (n = 196 
cores)
MET H-score med [P25–P75] p-value
Histological pattern
 Acinar 35 [0–280] 0.033
 Lepidic 400 [300–400]
 Solid 30 [0–400]
 Papillary 25 [0–78.5]
Histological grade
 1 360 [97.5–400] 0.010
 2 60 [0–200]
 3 30 [0–383]
Staining pattern
 Cytoplasmic 20 [7.25–160] 0.003
 Membranous 240 [40–400]
Vimentin
 Positive 0 [0–150] 0.027
 Negative 80 [50–340]
E-cadherin
 Positive 80 [1–350] 0.003
 Negative 0 [0–20]
TMA, Tissue microarray; IHC, immunohistochemistry
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treatment with Onartuzumab plus Erlotinib (HR 0.3; 
p = 0.06) [46]. Recently, data from a phase I/II trial 
with Crizotinib reported significant clinical responses 
in patients with MET amplification. Those patients 
with a MET/CEP7 ratio of ≥ 5.0 showed significantly 
better outcomes [36]. Although these results need to be 
confirmed in larger clinical trials, FISH-based criteria 
appear to be more adequate for patient selection. If 
MET status by FISH is less heterogeneous than MET 
IHC remains to be determined, as small numbers in our 
study (only three FISH positive cases in the TMA cohort) 
prevent us from drawing any robust conclusions.
Classically, it has been accepted that, after activation 
at the cell membrane, tyrosine-kinasereceptors (RTK) are 
internalized and degraded or recycled back to the membrane. 
However, during the last decade, preclinical evidence has 
emerged that highlights the role of receptor endocytosis 
and intracellular trafficking in RTK-mediated signaling 
[47–49]. In a preclinical model with immortalized bronchial 
cells, sustained stimulation with HGF caused a gradual 
displacement of c-MET receptor from the membrane to 
the cytoplasm [50]. Also, recent studies have associated the 
presence of cytoplasmic Met determined by IHC with tumor 
progression in patients with resected bladder cancer [51] and 
with poor outcome in patients with gastric adenocarcinoma 
[27] and mesothelioma [50]. Also, the presence of a 
mesenchymal phenotype, which can be an early event 
in NSCLC [52], has been linked to poor prognosis and 
metastasis development in surgically resected NSCLC [53].
Finally, our evaluation of potential surrogate 
markers for MET activation revealed interesting 
findings. Predominant cytoplasmic staining, which 
may translate MET pathway activation, was associated 
with a mesenchymal phenotype, which in turn can also 
be derived from MET HGF-dependent activation [34]. 
Although only hypothesis-generating, these results would 
Figure 6: Exploratory survival analyses in the TMA cohort. A. Overall survival of the whole cohort (n = 47 patients, median 
overall survival not reached). B. Survival according to MetMab status. C. Survival according to MET staining pattern. D. Survival according 
to epithelial or mesenchymal phenotype.
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be concordant with these patients presenting a worse 
prognosis, as observed in our limited series and harbor a 
potential predictive value for MET inhibitor benefit.
In conclusion, our study shows that MET status is 
highly heterogeneous within nsNSCLC tumors. This notion 
challenges current techniques and criteria for selecting 
patients for MET-targeted therapies. Further studies are 
needed to accurately detect patients with MET-driven tumors.
FINANCIAL SUPPORT
This work was supported by RD12/0036/0051 
/FEDER, PI13/00140/FEDER, a grant from Fundacio 
Marato de TV3. Ref.666/C/2013 and 2014 SGR 740. the 
“Xarxa de Bancs de tumors sponsored by Pla Director 
d’Oncologia de Catalunya (XBTC).” JA is recipient of 
intensification programme ISCIII.
REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 
Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N 
Engl J Med. 2008; 359:1367–80.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu 
DT, Saijo N, Sunpaweravong P, Han B, Margono B, 
Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib 
or  carboplatin-paclitaxel in pulmonary adenocarcinoma. 
N Engl J Med. 2009; 361:947–57.
4. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC. 
ALK translocation and crizotinib in non-small cell lung 
cancer: an evolving paradigm in oncology drug develop-
ment. Eur J Cancer. 2012; 48:961–73.
5. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-
Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, 
Salgia R, Fidias P, Engelman JA, et al. Activity and safety 
of crizotinib in patients with ALK-positive non-small-cell 
lung cancer: updated results from a phase 1 study. Lancet 
Oncol. 2012; 13:1011–9.
6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, 
Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, 
Porta R, Cobo M, Garrido P, et al. Erlotinib versus standard 
chemotherapy as first-line treatment for European patients 
with advanced EGFR mutation-positive non-small-cell lung 
cancer (EURTAC): a multicentre, open-label, randomised 
phase 3 trial. Lancet Oncol. 2012; 13:239–46.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, 
Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, 
Supko JG, Haluska FG, Louis DN, Christiani DC, 
Settleman J, et al. Activating mutations in the epidermal 
growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med. 2004; 
350:2129–39.
8. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande 
Woude G. Sequence of MET protooncogene cDNA has 
features characteristic of the tyrosine kinase family of 
growth-factor receptors. Proc Natl Acad Sci U S A. 1987; 
84:6379–83.
9. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, 
Comoglio PM. Tyrosine kinase receptor indistinguishable 
from the c-met protein. Nature. 1989; 339:155–6.
10. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-
mesenchymal transitions in development and disease. Cell. 
2009; 139:871–90.
11. Birchmeier C, Birchmeier W, Gherardi E, Vande 
Woude GF. Met, metastasis, motility and more. Nat Rev 
Mol Cell Biol. 2003; 4:915–25.
12. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. 
Targeting MET in cancer: rationale and progress. Nat Rev 
Cancer. 2012; 12:89–103.
13. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, 
Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, 
Lader A, Richards W, Sugarbaker D, Husain AN, et al. 
Functional expression and mutations of c-Met and its 
therapeutic inhibition with SU11274 and small interfer-
ing RNA in non-small cell lung cancer. Cancer Res. 2005; 
65:1479–88.
14. Takanami I, Tanana F, Hashizume T, Kikuchi K, 
Yamamoto Y, Yamamoto T, Kodaira S. Hepatocyte growth 
factor and c-Met/hepatocyte growth factor receptor in pul-
monary adenocarcinomas: an evaluation of their expression 
as prognostic markers. Oncology. 1996; 53:392–7.
15. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, 
Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, 
Incarbone M, Toschi L, Finocchiaro G, Destro A, et al. 
Increased MET gene copy number negatively affects sur-
vival of surgically resected non-small-cell lung cancer 
patients. J Clin Oncol. 2009; 27:1667–74.
16. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, 
Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, 
Jassem J, Hirsch FR. Correlation between MET gene copy 
number by silver in situ hybridization and protein expres-
sion by immunohistochemistry in non-small cell lung 
 cancer. J Thorac Oncol. 2012; 7:340–7.
17. Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, 
Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM, 
et al. High MET copy number and MET overexpression: 
poor outcome in non-small cell lung cancer patients. Histol 
Histopathol. 2012; 27:197–207.
18. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, 
Merchant M, Schwall R, Westphal M, Lamszus K. A 
novel one-armed anti-c-Met antibody inhibits glioblastoma 
growth in vivo. Clin Cancer Res. 2006; 12:6144–52.
19. Christensen JG, Burrows J, Salgia R. c-Met as a target for 
human cancer and characterization of inhibitors for thera-
peutic intervention. Cancer Lett. 2005; 225:1–26.
Oncotarget16225www.impactjournals.com/oncotarget
20. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, 
Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable 
complete response of metastatic gastric cancer with anti-
Met therapy followed by resistance at recurrence. Cancer 
Discov. 2011; 1:573–9.
21. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, 
Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, 
Maki RG, Clark JW, Wilner KD, et al. Rapid and dramatic 
radiographic and clinical response to an ALK inhibitor 
(crizotinib, PF02341066) in an ALK translocation-positive 
patient with non-small cell lung cancer. J Thorac Oncol. 
2010; 5:2044–6.
22. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, 
Soria JC, von Pawel J, Schwartz B, Von Roemeling R, 
Sandler AB. Rationale and design of MARQUEE: a phase 
III, randomized, double-blind study of tivantinib plus erlotinib 
versus placebo plus erlotinib in previously treated patients 
with locally advanced or metastatic, nonsquamous, non-small-
cell lung cancer. Clin Lung Cancer. 2012; 13:391–5.
23. Spigel DR, Edelman MJ, Mok T, O’Byrne K, Paz-Ares L, 
Yu W, Rittweger K, Thurm H. Treatment Rationale Study 
Design for the MetLung Trial: A Randomized, Double-
Blind Phase III Study of Onartuzumab (MetMAb) in 
Combination With Erlotinib Versus Erlotinib Alone in 
Patients Who Have Received Standard Chemotherapy 
for Stage IIIB or IV Met-Positive Non-Small-Cell Lung 
Cancer. Clin Lung Cancer. 2012; 13:500–4.
24. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, 
Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, 
Olivi A, McLendon R, Rasheed BA, et al. An integrated 
genomic analysis of human glioblastoma multiforme. 
Science. 2008; 321:1807–12.
25. Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, Zhai W, Cai J, 
Ling S, Gong Q, Chong Z, Qu Z, Li Q, Liu J, et al. Rapid 
growth of a hepatocellular carcinoma and the driving 
mutations revealed by cell-population genetic analysis 
of whole-genome data. Proc Natl Acad Sci U S A. 2011; 
108:12042–7.
26. Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, 
Marafioti T, Shende VH, McGranahan N, Rowan AJ, 
Hazell S, Hamm D, Robins HS, Pickering L, et al. Ultra-
deep T cell receptor sequencing reveals the complexity and 
intratumour heterogeneity of T cell clones in renal cell car-
cinomas. J Pathol. 2013; 231:424–32.
27. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, 
Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, et al. 
MET overexpression assessed by new interpretation method 
predicts gene amplification and poor survival in advanced 
gastric carcinomas. Mod Pathol. 2013; 26:1632–41.
28. Arriola E, Canadas I, Arumi-Uria M, Domine M, Lopez-
Vilarino JA, Arpi O, Salido M, Menendez S, Grande E, 
Hirsch FR, Serrano S, Bellosillo B, Rojo F, et al. MET 
phosphorylation predicts poor outcome in small cell lung 
carcinoma and its inhibition blocks HGF-induced effects 
in MET mutant cell lines. Br J Cancer. 2011; 105:814–23.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, 
Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, 
Kallioniemi OP. Tissue microarrays for high-throughput molec-
ular profiling of tumor specimens. Nat Med. 1998; 4:844–7.
30. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, 
Corzo C, Bellet M, Fabregat X, Serrano S, Sole F. 
Polysomy of chromosome 1 in breast cancer tumors 
 showing an overexpression of ERBB2: a study of 15 cases 
using fluorescence in situ hybridization and immunohisto-
chemistry. Breast Cancer Res. 2005; 7:R267–73.
31. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, 
Zhou Q, Crino L, Franklin WA, Varella-Garcia M. 
Optimizing the detection of lung cancer patients harbor-
ing anaplastic lymphoma kinase (ALK) gene rearrange-
ments potentially suitable for ALK inhibitor treatment. Clin 
Cancer Res. 2010; 16:5581–90.
32. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, 
Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, 
Ludovini V, Magrini E, Gregorc V, et al. Epidermal growth 
factor receptor gene and protein and gefitinib sensitivity 
in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 
97:643–55.
33. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt 
JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, 
Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, et al. 
Randomized phase II trial of Onartuzumab in combination 
with erlotinib in patients with advanced non-small-cell lung 
cancer. J Clin Oncol. 2013; 31:4105–14.
34. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, 
Pijuan L, Menendez S, Zazo S, Domine M, Salido M, 
Mojal S, Garcia de Herreros A, Rovira A, et al. Targeting 
Epithelial-to-Mesenchymal Transition with Met Inhibitors 
Reverts Chemoresistance in Small Cell Lung Cancer. Clin 
Cancer Res. 2014; 20:938–50.
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, 
Gion M, Clark GM. Statistics Subcommittee of the 
NCIEWGoCD. Reporting recommendations for tumor 
marker prognostic studies (REMARK). J Natl Cancer Inst. 
2005; 97:1180–4.
36. Camidge DR, Ou S-HI, Shapiro G, Otterson GA, 
Villaruz LC, Villalona-Calero MA, Iafrate AJ, Varella-
Garcia M, Dacic S, Cardarella S, Zhao W, Tye L, 
Stephenson P, et al. Efficacy and safety of crizotinib in 
patients with advanced c-MET-amplified non-small cell lung 
cancer (NSCLC). ASCO Meeting Abstracts. 2014; 32:8001.
37. Travis WD, Brambilla E, Riely GJ. New pathologic clas-
sification of lung cancer: relevance for clinical practice and 
clinical trials. J Clin Oncol. 2013; 31:992–1001.
38. Fisher R, Larkin J, Swanton C. Inter and intratumour het-
erogeneity: a barrier to individualized medical therapy in 
renal cell carcinoma? Front Oncol. 2012; 2:49.
39. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, 
Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, 
Velculescu VE, Kinzler KW, Vogelstein B, et al. Distant 
Oncotarget16226www.impactjournals.com/oncotarget
metastasis occurs late during the genetic evolution of 
 pancreatic cancer. Nature. 2010; 467:1114–7.
40. Cancer Genome Atlas Research N: Comprehensive molec-
ular profiling of lung adenocarcinoma. Nature. 2014; 
511:543–50.
41. Chen Z, Fillmore CM, Hammerman PS, Kim CF, 
Wong KK. Non-small-cell lung cancers: a heterogeneous 
set of diseases. Nat Rev Cancer. 2014; 14:535–46.
42. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of 
MET gene copy number and protein expression in patients 
with surgically resected non-small cell lung cancer: a 
meta-analysis of published literatures. PLoS One. 2014; 
9:e99399.
43. Xiu J, Feldman R, Bender RP, Salgia R. Tumor biomarker 
evaluation of 6, 785 patients for combination treatment 
strategies in NSCLC. ASCO Meeting Abstracts. 2014; 
32:e19012.
44. Sequist LV, von Pawel J, Garmey EG, Akerley WL, 
Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, 
Orlov S, Ramlau R, Arthur S, Gorbachevsky I, et al. 
Randomized phase II study of erlotinib plus tivantinib 
 versus erlotinib plus placebo in previously treated non-
small-cell lung cancer. J Clin Oncol. 2011; 29:3307–15.
45. Novello S, Scagliotti GV, Ramlau R, Barlesi F, Sandler AB, 
Von Roemeling R. Efficacy Analysis for Molecular 
Subgroups in MARQUEE: a Randomized, Double-blind, 
Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) 
Plus Erlotinib versus Placebo plus Erlotinib in Previously 
Treated Patients with Locally Advanced or Metastatic, 
 Non-squamous, Non- small Cell Lung Cancer (NSCLC). 
Poster presented at: World Congress on Lung Cancer; 2013 
27–31; Sidney, Australia.
46. Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, 
Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, 
et al. Biomarker Analyses from a Placebo-Controlled 
Phase II Study Evaluating Erlotinib +/– Onartuzumab in 
Advanced Non-Small Cell Lung Cancer: MET Expression 
Levels Are Predictive of Patient Benefit. Clin Cancer Res. 
2014; 20:4488–98.
47. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, 
Kermorgant S. A direct role for Met endocytosis in tumori-
genesis. Nat Cell Biol. 2011; 13:827–37.
48. Barrow R, Joffre C, Menard L, Kermorgant S. Measuring 
the role for Met endosomal signaling in tumorigenesis. 
Methods Enzymol. 2014; 535:121–40.
49. von Zastrow M, Sorkin A. Signaling on the endocytic path-
way. Curr Opin Cell Biol. 2007; 19:436–45.
50. Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, 
Brochard P, Astoul P, Pairon JC, Bergot E, Zalcman G, 
Galateau-Salle F. Plasma cell membrane localization of 
c-MET predicts longer survival in patients with malignant 
mesothelioma: a series of 15 cases from the MESOPATH 
Group. J Thorac Oncol. 2012; 7:599–606.
51. Kluth M, Reynolds K, Rink M, Chun F, Dahlem R, 
Fisch M, Hoppner W, Wagner W, Doh O, Terracciano L, 
Simon R, Sauter G, Minner S. Reduced membranous MET 
expression is linked to bladder cancer progression. Cancer 
Genet. 2014; 207:147–52.
52. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, 
Tang X, Brown KC, Bekele BN, Moran C, Wistuba II. 
Epithelial-to-mesenchymal transition in the development 
and progression of adenocarcinoma and squamous cell car-
cinoma of the lung. Mod Pathol. 2009; 22:668–78.
53. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-
Hensch N, Weder W, Moch H, Kristiansen G. Prognostic 
significance of epithelial-mesenchymal and mesenchymal-
epithelial transition protein expression in non-small cell 
lung cancer. Clin Cancer Res. 2008; 14:7430–7.
